Colleen Tupper serves as the Executive Vice President and Chief Financial Officer at Collegium Pharmaceutical Inc., a role she has held since joining the company in 2018. With a robust background in finance and strategic leadership within the pharmaceutical industry, Tupper has been instrumental in steering Collegium's financial strategy and growth. Prior to her current position, she spent over a decade at Shire Pharmaceuticals, where she held various senior financial roles, including Senior Vice President of Finance. Her experience at Shire was marked by her involvement in significant corporate transactions, such as mergers and acquisitions, which enhanced the company's portfolio and market presence. At Collegium, Tupper has played a pivotal role in navigating the company through a period of substantial growth and transformation. Her strategic oversight has been crucial in managing the company's financial operations, including capital allocation and investor relations. Under her leadership, Collegium successfully acquired the rights to Xtampza ER, a key product in their portfolio, which has been a significant driver of the company's revenue growth. Tupper's expertise in financial planning and analysis has also been vital in maintaining a strong balance sheet, enabling the company to invest in research and development while ensuring sustainable profitability. Colleen Tupper's contributions extend beyond her financial acumen; she is recognized for her commitment to fostering a culture of accountability and innovation at Collegium. Her leadership style emphasizes transparency and collaboration, which has helped build a cohesive executive team focused on achieving long-term strategic goals. Tupper's role as CFO is not only about managing numbers but also about shaping the company's future through strategic decision-making and fostering a supportive work environment. Her dedication to Collegium's mission to provide innovative solutions for pain management has made her an invaluable asset to the organization.